The effect of velnacrine on the mixed function oxidase system

[1]  V. Bigl,et al.  Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease , 2004, Acta Neuropathologica.

[2]  S. Wrighton,et al.  Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[3]  B. K. Park,et al.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. , 1994, British journal of clinical pharmacology.

[4]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[5]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[6]  R. Combes,et al.  Interaction of Cimetidine with Cytochrome P450 and Effect on Mixed-Function Oxidase Activities of Liver Microsomes , 1993, Human & experimental toxicology.

[7]  F. Huff,et al.  Evaluation of HP 029 (Velnacrine Maleate) in Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[8]  R. Edwards,et al.  Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. , 1990, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  A. Bast,et al.  Identification of structural characteristics of some potential H2-receptor antagonists that determine the interaction with rat hepatic P-450. , 1988, Chemico-biological interactions.

[10]  R. Gugler,et al.  Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. , 1985, Biochemical pharmacology.

[11]  S. Mirra,et al.  The nucleus basalis of Meynert in neurological disease: A quantitative morphological study , 1985, Annals of neurology.

[12]  Vahram Haroutunian,et al.  Development of cholinergic drugs for the treatment of Alzheimer's disease , 1985 .

[13]  J. Houston,et al.  Inhibition of antipyrine metabolite formation in rats in vivo. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  A. Bast,et al.  Inhibition of mono-oxygenase and oxidase activity of rat-hepatic cytochrome P-450 by H2-receptor blockers. , 1984, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  J. Powell,et al.  The Pharmacokinetic Basis for H2‐antagonist Drug Interactions: Concepts and Implications , 1983, Journal of clinical gastroenterology.

[16]  D. Breimer.  Interindividual Variations in Drug Disposition , 1983, Clinical pharmacokinetics.

[17]  E. Perry,et al.  Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases , 1983, Journal of the Neurological Sciences.

[18]  E. Sorkin,et al.  Review of Cimetidine Drug Interactions , 1983, Drug intelligence & clinical pharmacy.

[19]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[20]  R. Knodell,et al.  Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists , 1982 .

[21]  A. Somogyi,et al.  Drug Interactions with Cimetidine , 1982, Clinical pharmacokinetics.

[22]  O. Pelkonen,et al.  The effect of cimetidine on in vitro and in vivo microsomal drug metabolism in the rat. , 1980, Biochemical pharmacology.

[23]  W. Kalow,et al.  Antipyrine metabolism in the rat by three hepatic monooxygenases. , 1980, Life sciences.